TTRX

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows: Date: September 23, 2026 Time: 1:30 PM ET The presentation will provide a detailed look at the Company’s atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and emerging findings across distinct patient populations. These include patients with moderate-severe baseline pruritus, as well

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Brings internationally recognized expertise in immunology, cytokine biology, host-microbe interactions and public health Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today announced the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer. Dr. Redfield brings more than four decades of experience in immunology, microbiology, infectious disease, clinical research, and public health. He has authored an extensive body of scientific literature cited more than 35,000 times, including research examining cytokine signaling and the biological interactions bet

Martin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic advisory experience ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced the appointment of Martin Dewhurst to its Board of Directors (the "Board") as an independent director, and as a member of both the Audit Committee and the Compensation Committee, e

D - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

10-Q - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027 Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027 Turn Therapeutics Inc. (NASDAQ:TTRX), a

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark its progress to date. "We're honored that Nasdaq invited us back to share our story," said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. "Over the past year we've made meaningful progress, but

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a si

Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the optimized Stage 2 study design that will guide completion of the Phase 2 program. Following the preliminary interim assessment announced in June, the Company conducted a detailed multi-week review of the Stage 1 dataset within the trial's ad

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for infla

8-K - Turn Therapeutics Inc. (0002023016) (Filer)